Telix Pharmaceuticals |
High $11.49 |
Low $11.20 |
Trades 4,718 |
Turnover $7,499,551 |
Volume 664,557 |
| 30 June 2023 at 4:12pm | ||||
|
Market Cap (14-Nov) $4,655,044,608 (204th) |
Close (30-Jun) $11.22 |
Volume (30-Jun) 664,557 |
Shortsold (9-Nov) 35,408,995 (10.40%) (16th) |
|
52w High $18.22 |
52w Low $8.26 |
P/E 178.57 |
EPS 0.15 |
Telix Preclinical Development of Radiolabelled Olaratumab
TLX released this announcement to the ASX on 17 April 2023, 8:23. The announcement is marked as price sensitive, and is 3 page(s) in length and 136.72kb in size.
You can view all announcements from TLX and see how they appear on a price chart on the announcements page.
At the date of this announcement, TLX was 0.992% short sold according to ASIC data. It was ranked the 220th most shorted stock on the ASX. It is now ranked as the 16th most shorted stock on the ASX with 10.404% of total shares short sold as of the latest reported data (09 November 2026).
| Other Recent Announcements from TLX | |
|---|---|
| Cleansing Notice | 28 June 2023, 8:23 |
| Application for quotation of securities - TLX | 28 June 2023, 8:23 |
| Proposed issue of securities - TLX | 21 June 2023, 18:12 |
| Telix Preclinical Development of Radiolabelled Olaratumab | 17 April 2023, 8:23 |
| Notification of upcoming quarterly results and investor call | 5 April 2023, 8:16 |
| Notification of cessation of securities - TLX | 5 April 2023, 8:16 |
| Cleansing Notice | 5 April 2023, 8:16 |
If you were already registered, log in here.